IDEAS home Printed from https://ideas.repec.org/e/pgr189.html
   My authors  Follow this author

Paul Vincent Grootendorst

Personal Details

First Name:Paul
Middle Name:Vincent
Last Name:Grootendorst
Suffix:
RePEc Short-ID:pgr189
[This author has chosen not to make the email address public]
http://individual.utoronto.ca/grootendorst/

Affiliation

(10%) Munk School of Global Affairs and Public Policy
University of Toronto

Toronto, Canada
https://munkschool.utoronto.ca/
RePEc:edi:spputca (more details at EDIRC)

(80%) University of Toronto, Faculty of Pharmacy

http://www.pharmacy.utoronto.ca/
Canada, Toronto

(10%) Department of Economics
McMaster University

Hamilton, Canada
http://www.mcmaster.ca/economics/
RePEc:edi:demcmca (more details at EDIRC)

Research output

as
Jump to: Working papers Articles Chapters

Working papers

  1. Oliver Spicer & Paul Grootendorst, 2020. "An Empirical Examination of the Patented Medicine Prices Review Board Price Control Amendments on Drug Launches in Canada," Working Papers 200003, Canadian Centre for Health Economics.
  2. Rebeira, Mayvis & Grootendorst, Paul V. & Coyte, Peter C. & Aguirregabiria, Victor, 2017. "Does rising income inequality affect mortality rates in advanced economies?," Economics Discussion Papers 2017-12, Kiel Institute for the World Economy (IfW Kiel).
  3. Paul Grootendorst & Minsup Shim & Adam Falconi & Tyler Robinson & Ethar Ismail & Joel Lexchin, 2015. "Intellectual Property Protection And Drug Plan Coverage: Evidence From Ontario," Working Papers 150005, Canadian Centre for Health Economics.
  4. Guy E.J. Faulkner & Paul Grootendorst & Van Hai Nguyen & Tatiana Andreyeva & Kelly Arbour-Nicitopoulos & Chris Auld & Sean B. Cash & John Cawley & Peter Donnelly & Adam Drewnowski & Laurette Dubé & R, 2011. "Economic Instruments for Obesity Prevention: Results of a Scoping Review and Modified Delphi Survey," Monash Economics Working Papers 31-11, Monash University, Department of Economics.
  5. Paul Grootendorst & Aidan Hollis & David K Levine & Thomas Pogge & Aled M Edwards, 2010. "New Approaches to Rewarding Pharmaceutical Innovation," Levine's Bibliography 661465000000000169, UCLA Department of Economics.
  6. Paul Grootendorst, 2009. "How should we support pharmaceutical innovation?," Social and Economic Dimensions of an Aging Population Research Papers 246, McMaster University.
  7. Paul Grootendorst, 2009. "Patents, Public-Private Partnerships or Prizes – How should we support pharmaceutical innovation?," Social and Economic Dimensions of an Aging Population Research Papers 250, McMaster University.
  8. Paul Grootendorst & Emmanuelle Piérard & Minsup Shim, 2007. "The life expectancy gains from pharmaceutical drugs: a critical appraisal of the literature," Social and Economic Dimensions of an Aging Population Research Papers 221, McMaster University.
  9. Paul Grootendorst, 2007. "A review of instrumental variables estimation in the applied health sciences," Social and Economic Dimensions of an Aging Population Research Papers 215, McMaster University.
  10. Paul Grootendorst, 2007. "Effects of 'Authorized-Generics' on Canadian Drug Prices," Social and Economic Dimensions of an Aging Population Research Papers 201, McMaster University.
  11. Paul V. Grootendorst & John K. Marshall & Anne M. Holbrook & Lisa R. Dolovich & Bernie J. O'Brien & Adrian R. Levy, 2004. "The Impact of Differential Cost Sharing of Non-Steroidal Anti-Inflammatory Agents on the Use and Costs of Analgesic Drugs," Social and Economic Dimensions of an Aging Population Research Papers 115, McMaster University.
  12. Thomas F. Crossley & Paul V. Grootendorst & Michael R. Veall, 2003. "National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations?," Quantitative Studies in Economics and Population Research Reports 385, McMaster University.
  13. Alan, Sule & Crossley, Thomas F. & Grootendorst, Paul & Veall, Michael R., 2003. "Out-of-Pocket Prescription Drug Expenditures and Public Prescription Drug Programs," IZA Discussion Papers 695, Institute of Labor Economics (IZA).
  14. Paul Grootendorst & Mitchell Levine, 2002. "Do Drug Plans Matter? Effects of Drug Plan Eligibility on Drug Use Among the Elderly, Social Assistance Recipients and the General Population," Quantitative Studies in Economics and Population Research Reports 372, McMaster University.
  15. Paul V. Grootendorst & Lisa R. Dolovich & Anne M. Holbrook & Adrian R. Levy & Bernie J. O'Brien, 2002. "The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia -- Volume II: Technical Report," Quantitative Studies in Economics and Population Research Reports 370, McMaster University.
  16. Paul V. Grootendorst & Lisa R. Dolovich & Anne M. Holbrook & Adrian R. Levy & Bernie J. O'Brien, 2002. "The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia -- Volume I: Summary," Quantitative Studies in Economics and Population Research Reports 369, McMaster University.
  17. Donald Willison & Mary Wiktorowicz & Paul Grootendorst & Bernie O'Brien & Mitchell Levine & Raisa Deber & Jeremiah Hurley, 2001. "International Experience With Pharmaceutical Policy: Common Challenges and Lessons for Canada," Centre for Health Economics and Policy Analysis Working Paper Series 2001-08, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.
  18. Thomas F. Crossley & Paul Grootendorst & Sule Kokkmaz & Michael R. Veall, 2000. "The Effects of Drug Subsidies on Out-of-Poket Prescription Drug Expenditures by seniors: regional Evidence from Canada," CEPR Discussion Papers 422, Centre for Economic Policy Research, Research School of Economics, Australian National University.
  19. P Grootendorst & D Feeny & W Furlong, 1999. "Health Utilities Index Mark 3: Evidence of Construct Validity for Stroke and Arthritis in a Population Health Survey," Centre for Health Economics and Policy Analysis Working Paper Series 1999-06, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.
  20. P Grootendorst, 1999. "Beneficiary Cost Sharing Under Canadian Provincial Prescription Drug Benefit Programs: History and Assessment," Centre for Health Economics and Policy Analysis Working Paper Series 1999-10, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.
  21. Paul Grootendorst & David Feeney & W. Furlong, 1999. "Evidence of Construct Validity for Stoke and Arthritis in a Population Health Survey," Department of Economics Working Papers 1999-09, McMaster University.
  22. Donald Willison & Paul Grootendorst & Jeremiah Hurley, 1998. "Variance in Pharmacare Coverage Across Canada," Centre for Health Economics and Policy Analysis Working Paper Series 1998-08, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.
  23. Paul Grootendorst & Laurie Goldsmith & Jeremiah Hurley & Bernie O'Brien & Lisa Dolovich, 1996. "Financial Incentives to Dispense Low-Cost Drugs: A Case Study of British Columbia Pharmacare," Centre for Health Economics and Policy Analysis Working Paper Series 1996-08, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.
  24. P Grootendorst & B O'Brien & G Anderson, 1995. "On Becoming 65 in Ontario: Effects of Provincial Drug Plan Eligibility on Utilization of Prescription Medicines," Centre for Health Economics and Policy Analysis Working Paper Series 1995-01, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.
  25. P Grootendorst & D Feeny & W Furlong, 1994. "Does It Matter Whom and How You Ask? Inter and Intra-rater Agreement in the Ontario Health Survey," Centre for Health Economics and Policy Analysis Working Paper Series 1994-12, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.
  26. Paul Grootendorst, 1993. "Results of an Investigation into the Integrity of the Ontario Health Survey," Centre for Health Economics and Policy Analysis Working Paper Series 1993-11, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.
  27. Christopher Auld & Paul Grootendorst, "undated". "An Empirical Analysis of Milk Addiction," Working Papers 2001-17, Department of Economics, University of Calgary, revised 05 Dec 2001.

Articles

  1. Spicer, Oliver & Grootendorst, Paul, 2022. "The effect of patented drug price on the share of new medicines across OECD countries," Health Policy, Elsevier, vol. 126(8), pages 795-801.
  2. Rebeira, Mayvis & Grootendorst, Paul & Coyte, Peter C. & Aguirregabiria, Victor, 2017. "Does rising income inequality affect mortality rates in advanced economies?," Economics - The Open-Access, Open-Assessment E-Journal (2007-2020), Kiel Institute for the World Economy (IfW Kiel), vol. 11, pages 1-23.
  3. Kavisha Jayasundara & Murray Krahn & Muhammad Mamdani & Jeffrey S. Hoch & Paul Grootendorst, 2017. "Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology," PharmacoEconomics - Open, Springer, vol. 1(3), pages 167-173, September.
  4. Ali Shajarizadeh & Paul Grootendorst & Aidan Hollis, 2015. "Newton's First Law as Applied to Pharmacies: Why Entry Order Matters for Generics," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 22(2), pages 201-217, July.
  5. Emmanuelle Pi鲡rd & Paul Grootendorst, 2014. "Do downturns cause desperation? The effect of economic conditions on suicide rates in Canada," Applied Economics, Taylor & Francis Journals, vol. 46(10), pages 1081-1092, April.
  6. Morgan, Steve & Grootendorst, Paul & Lexchin, Joel & Cunningham, Colleen & Greyson, Devon, 2011. "The cost of drug development: A systematic review," Health Policy, Elsevier, vol. 100(1), pages 4-17, April.
  7. Marshall, Deborah A. & Willison, Donald J. & Grootendorst, Paul & LeLorier, Jacques & Maclure, Malcolm & Kulin, Nathalie A. & Sheehy, Odile E. & Warren, Leanne & Sykora, Kathy & Rahme, Elham, 2007. "The effects of coxib formulary restrictions on analgesic use and cost: Regional evidence from Canada," Health Policy, Elsevier, vol. 84(1), pages 1-13, November.
  8. Paul Grootendorst & David Stewart, 2006. "A re‐examination of the impact of reference pricing on anti‐hypertensive drug plan expenditures in British Columbia," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 735-742, July.
  9. Paul Contoyannis & Jeremiah Hurley & Paul Grootendorst & Sung‐Hee Jeon & Robyn Tamblyn, 2005. "Estimating the price elasticity of expenditure for prescription drugs in the presence of non‐linear price schedules: an illustration from Quebec, Canada," Health Economics, John Wiley & Sons, Ltd., vol. 14(9), pages 909-923, September.
  10. Paul V. Grootendorst & Michael R. Veall, 2005. "National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations?," Canadian Public Policy, University of Toronto Press, vol. 31(4), pages 341-358, December.
  11. Sule Alan & Thomas Crossley & Paul Grootendorst & Michael Veall, 2005. "Distributional effects of `general population' prescription drug programs in Canada," Canadian Journal of Economics, Canadian Economics Association, vol. 38(1), pages 128-148, February.
  12. Auld, M. Christopher & Grootendorst, Paul, 2004. "An empirical analysis of milk addiction," Journal of Health Economics, Elsevier, vol. 23(6), pages 1117-1133, November.
  13. Alan, Sule & Crossley, Thomas F. & Grootendorst, Paul & Veall, Michael R., 2002. "The effects of drug subsidies on out-of-pocket prescription drug expenditures by seniors: regional evidence from Canada," Journal of Health Economics, Elsevier, vol. 21(5), pages 805-826, September.
  14. Schneeweiss, Sebastian & Maclure, Malcolm & Walker, Alexander M. & Grootendorst, Paul & Soumerai, Stephen B., 2001. "On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective," Health Policy, Elsevier, vol. 55(2), pages 97-109, February.
  15. Paul V. Grootendorst, 1997. "Health care policy evaluation using longitudinal insurance claims data: An application of the Panel Tobit estimator," Health Economics, John Wiley & Sons, Ltd., vol. 6(4), pages 365-382, July.

Chapters

  1. Paul Grootendorst, 2012. "Prescription Drug Insurance and Reimbursement," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 11, Edward Elgar Publishing.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 17 papers announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.
  1. NEP-HEA: Health Economics (13) 2000-10-23 2002-11-18 2002-11-18 2002-11-18 2003-01-12 2003-02-10 2003-08-24 2004-12-12 2007-10-06 2010-10-02 2012-01-10 2015-05-09 2017-04-02. Author is listed
  2. NEP-IPR: Intellectual Property Rights (4) 2009-05-23 2009-08-08 2010-10-02 2015-05-09
  3. NEP-COM: Industrial Competition (3) 2003-01-12 2007-08-27 2015-05-09
  4. NEP-INO: Innovation (3) 2009-05-23 2009-08-08 2010-10-02
  5. NEP-AGR: Agricultural Economics (1) 2012-01-10
  6. NEP-ECM: Econometrics (1) 2007-08-27
  7. NEP-KNM: Knowledge Management and Knowledge Economy (1) 2009-05-23
  8. NEP-LAW: Law and Economics (1) 2015-05-09
  9. NEP-MIC: Microeconomics (1) 2009-05-23
  10. NEP-PKE: Post Keynesian Economics (1) 2003-02-10

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Paul Vincent Grootendorst should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.